In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Legend Biotech (LEGN – Research Report).
Zacks.com on MSN3d
Legend Biotech (LEGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowShares of Legend Biotech Corporation Sponsored ADR (LEGN) have been struggling lately and have lost 9.8% over the past week.
Legend Biotech Corp (NASDAQ:LEGN) received approval for CARVYKTI production in Belgium, expanding its manufacturing capacity ...
Although the revenue and EPS for Legend Biotech (LEGN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with ...
Legend Biotech Corporation (NASDAQ:LEGN) Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, ...
In a report released today, Sami Corwin from William Blair maintained a Hold rating on Legend Biotech (LEGN – Research Report). The ...
On Tuesday, Legend Biotech Corp (LEGN) stock saw a modest uptick, ending the day at $44.62 which represents a slight increase of $1.01 or 2.32% from the prior close of $43.61. The stock opened at $45 ...
Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback